Batch 001 - Live Allocation

3/100 SoldQ4 launch pricing · ends 31 Dec

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

AMYLIN AGONISTPhase 3 (combo)Popular · Amylin Adjunct

Cagrilintide

Amylin Analog · 10mg

Status

Phase 3 (combo)

Route

SubQ

Half-life

~7-8 days

Class

Amylin analog

MechanismAmylin Receptor Activation

Cohort24 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability is a question for your own doctor. See Informed Consent & Disclaimer.

V-Series Member

$76.95 USD/vial

À-la-carte: $81 USD/vial · Save 5%

Q4 launch pricing until 31 Dec · regular $90 USD/vial from 1 Jan

Vials per allocation

Member total (1×)$76.95

À-la-carte total$81

Flat per-vial pricing. International shipping $35, free on orders of $250 or more.

What this is

Long-acting amylin analog on a pathway separate from GLP-1. Used as an optional GLP-1 stack (the CagriSema rationale) or as an alternate-pathway bridge during a GLP-1 break.

Amylin Analog · 10mg per vial · lot-tested.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Lot-Tested

Every lot, independent lab

Report and verification code per lot

Cagrilintide · Amylin Agonist

◆ Certificate of Analysis · Cagrilintide

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot testing in progress. The independent lab report for this Cagrilintide lot will be published here, with its verification code, as soon as it is back.

◉

Clinical Overview

Cagrilintide

Cagrilintide is a long-acting amylin analog. It works through the amylin and calcitonin receptor system - a pathway entirely separate from GLP-1 - to regulate appetite and gastric emptying.

This mechanistic independence is what makes it useful both alongside a GLP-1 agonist and as an alternate-pathway option.

✦

Amylin Pathway

Agonist at amylin/calcitonin receptors - separate from GLP-1.

◈

Satiety Signaling

Acts on brainstem satiety centers; slows gastric emptying.

❤

Combination Evidence

Phase 3 data strongest in combination with a GLP-1 (CagriSema).

◈

Mechanism

How It Works

Non-selective agonist at amylin receptors (AMY1-3R) and the calcitonin receptor, concentrated in the area postrema and nucleus tractus solitarius of the brainstem. Generates satiety signals, slows gastric emptying, and suppresses post-meal glucagon.

Because it does not act on GLP-1 receptors, its effect is additive to incretin agonists rather than overlapping.

✚

Patient Bloodwork Guide

Bloodwork for Metabolic & Weight Protocols

GLP-1 class - Tirzepatide, Retatrutide, Semaglutide, Cagrilintide, V-03, V-M2

These protocols work on appetite, insulin sensitivity, and how your body stores fat. Monitoring tracks both the metabolic benefit and the things that change quickly during weight loss - blood sugar, lipids, and lean-mass markers.

Incremental approach. Doses are titrated upward slowly from a low starting point. Maintenance is typically a moderate dose - pushing higher rarely adds benefit and adds side effects. Monitoring guides where you settle.

Blood sugar & insulin

Fasting insulinTracks insulin sensitivity - usually the first thing to improve.

HbA1cYour 3-month average blood sugar.

Fasting glucoseRoutine blood-sugar tracking.

Heart & lipids

Full lipid panelLDL, HDL, triglycerides, ApoB - these shift meaningfully during weight loss.

Resting heart rate & BPSimple checks tracked through the protocol.

Muscle & body composition

IGF-1Helps protect lean mass during rapid weight loss.

DEXA / body compositionConfirms you are losing fat, not muscle - the goal of pairing with resistance training.

Overall safety

CMP & liver enzymesKidney and liver function (AST/ALT), watched especially when compounds are combined.

ThyroidBaseline check, as thyroid influences metabolic rate.

When the tests happen

BaselineCMP, HbA1c, fasting insulin, full lipids, liver, thyroid, IGF-1, DEXA.

Weeks 4 / 8 / 12 / 16Weight, resting HR, BP, symptom check.

QuarterlyCMP, HbA1c, fasting insulin, lipids, liver, IGF-1, body composition.

Educational only - not medical advice or a dosing instruction. Your own doctor orders tests, interprets results and decides what is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Long-acting amylin analogue
Mechanism	Amylin-receptor signalling; satiety and gastric-emptying modulation
Terminal half-life	Long-acting - once-weekly dosing studied in trials
Metabolism	Peptide degradation
Evidence base	Investigational - clinical trial stage, often studied with semaglutide
Regulatory status	Investigational; research use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Investigational. Educational only; not a dosing instruction.

Clinical Literature

Peer-Reviewed References

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)

Garvey WT, Blüher M, Osorto Contreras CK, et al. · 2025 · New England Journal of Medicine 2025;393(7):635–647

▾

Findings

Phase 3a, 68-week RCT (n=3,417, without type 2 diabetes; NCT05567796) of the fixed-dose combination CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) versus each agent alone and placebo. Mean weight change was −20.4% with the combination versus −11.5% cagrilintide alone, −14.9% semaglutide alone, and −3.0% placebo (−22.7% under full adherence). This is the primary evidence for the STACK rationale - co-administering cagrilintide with a GLP-1, where two independent satiety pathways (amylin and incretin) act together. IMPORTANT SCOPE: this trial tests continuous co-administration. It does NOT evaluate using cagrilintide during a break from a GLP-1, and provides no evidence for "receptor resensitizing" - that bridge use is a separate, mechanistically-plausible-but-unproven hypothesis and should not be inferred from this result.

View on publisher ↗

The REDEFINE 1 trial supports cagrilintide as part of a co-administered combination (the CagriSema stack). The separate "bridge during a GLP-1 break / resensitize" use pattern is NOT established by this or any combination/sequencing outcome trial; see the compound page for how Vivre tiers these two use patterns by evidence. Cagrilintide is sold for research use only.

◇

Clinical Applications

Indications

Amylin-pathway appetite regulation, distinct from incretin mechanisms
Optional stack with a GLP-1 agonist (the CagriSema rationale) for greater response at lower doses of each
Alternate-pathway option during a GLP-1 break
People exploring multi-pathway appetite regulation

⇄

Stack & Bridge Rationale

Two use patterns - tiered by evidence

Two use patterns, tiered by evidence: (1) STACK - co-administering cagrilintide with a GLP-1 agonist mirrors CagriSema. This has the strongest support: REDEFINE 1 showed the combination (−20.4%) substantially exceeded either drug alone, consistent with two independent satiety pathways firing together and allowing lower doses of each to reduce GI side effects.

(2) BRIDGE during a GLP-1 break - using cagrilintide's separate amylin pathway to maintain appetite control while a patient is off their GLP-1. This is mechanistically plausible (cagrilintide does not rely on GLP-1 receptors) but is NOT supported by combination/sequencing outcome trials; the popular "receptor resensitizing" framing is largely unproven - plateaus are more often metabolic adaptation than receptor downregulation.

The bridge is not an established protocol, and that uncertainty is stated here.

Stack evidence
Garvey WT, Blüher M, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med 2025;393(7):635–647. DOI 10.1056/NEJMoa2502081 ↗
Supports the stack (continuous co-administration) only - does not evaluate the bridge/break use or "resensitizing."

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~7-8 days (acylated for once-weekly dosing). Amylin/calcitonin agonist; mechanistically independent of the GLP-1 axis.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Phase 3 REDEFINE program (NEJM, June 2025). REDEFINE 1 (n=3,417, no diabetes, 68 wks): CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) −20.4% body weight (−22.7% with full adherence) vs cagrilintide alone −11.5%, semaglutide alone −14.9%, placebo −3%. REDEFINE 2 (n=1,206, type 2 diabetes): CagriSema −13.7% vs placebo −3.1%. Cagrilintide is not yet a standalone FDA-approved drug; Novo Nordisk's route to market is the CagriSema fixed-dose combination.

Dosing protocols, administration frequency, and titration schedules are not published on these public pages.

◎

Commonly Paired

Compounds Often Paired With Cagrilintide

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions.

Incretin Mimetic

Tirzepatide

Base Form · 10mg

◆ incretin stack

Cagrilintide (amylin analog) paired with incretin agonism - amplifies satiety signaling through a complementary receptor pathway. Combination therapy in advanced metabolic protocols.

View Tirzepatide detail →

Growth Hormone Secretagogue

Tesamorelin

GHRH Analog · 10mg

◆ lean-mass support

Tesamorelin preserves lean mass during accelerated weight loss when combined with metabolic agents.

View Tesamorelin detail →

FOR CUSTOMERS

Mixing guide and dosage calculator

Unlocks once you order Cagrilintide: step-by-step mixing with illustrations, storage, and a calculator that converts any dose to syringe units at your vial strength.

READY TO PROCEED

Start with the Biological Audit

Cagrilintide is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$76.95 USD/vial

Cagrilintide · Member rate